Ocrelizumab Efficacy and Safety in Relapsing Multiple Sclerosis

Monitoring and Treatment Response

• Brain MRI should be obtained at baseline and repeated within 3-12 months, then at least annually for stable patients, according to Praxis Medical Insights 1
• Be aware of pseudoatrophy effect, which should not be mistaken for disease progression, as noted by Praxis Medical Insights 2, 1
• Clinical assessments should evaluate relapses, MRI activity, and disability progression to determine treatment response, as recommended by Praxis Medical Insights 2

Comparative Efficacy of Interventions

• Vitamin D supplementation and nutritional interventions show no significant benefit for reducing relapses in MS, as reported in Clinical Nutrition 3, 4, 5
• Ocrelizumab's mechanism involves selective CD20+ B-cell depletion, addressing a key pathogenic component of MS, as described by Praxis Medical Insights 2